ImmunoScape, a Singapore and San Diego, CA-based biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, completed a $14m funding round.
The round, which brought total funding to $25m, was led by existing investors Anzu Partners, University of Tokyo Edge Capital Partners (UTEC) and new investor EDBI, an investment arm of the Economic Development Board of Singapore.
The company intends to use the funds to enlarge its team, further its expansion into the U.S., scale up its newly announced San Diego laboratory, and continue advancing the capabilities of its Deep Immunomics platform that enables the characterization of a patient’s immunome at ultra-high resolution.
Led by Choon Peng Ng, CEO, ImmunoScape provides a Deep Immunomics platform that integrates single-cell analysis technologies and bioinformatics for both drug discovery and high-dimensional immune profiling.
The company’s platform combines mass cytometry, single cell sequencing, and proprietary computational bioinformatics, data analysis, and visualization tools to provide novel, reproducible immune profiling information.
Kalyn Schieffer for ImmunoScape and Anzu Partners